Influenza Vaccines Clinical Trial
Official title:
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates: Colorado
Verified date | June 2019 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite U.S. guidelines for influenza vaccination of all children starting at age 6 months, only about half of children are vaccinated annually leading to substantial influenza disease in children and spread of disease to adults. A major barrier is that families are not reminded about the need for their children to receive influenza vaccination. The investigators will evaluate the impact of patient reminder/recall (R/R) performed by state immunization information systems to improve influenza vaccination rates by using three clinical trials in two states. The investigators will assess effectiveness and cost-effectiveness of phone reminder/recall on improving influenza vaccination rates. The investigators will disseminate the state immunization information system based reminder/recall system to all states for use for both seasonal and pandemic influenza vaccinations with the goal of lowering influenza morbidity.
Status | Completed |
Enrollment | 56549 |
Est. completion date | April 30, 2019 |
Est. primary completion date | April 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 18 Years |
Eligibility |
Inclusion Criteria: - A record in the Colorado Immunization Information System, - In need of at least one influenza vaccination at time of study, - Affiliated with a participating practice, or - Randomly selected among unaffiliated patients. Exclusion Criteria: - Opted out of participating in CIIS, or - Are up-to-date on influenza vaccine |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | National Institute of Allergy and Infectious Diseases (NIAID) |
Kempe A, Saville A, Dickinson LM, Eisert S, Reynolds J, Herrero D, Beaty B, Albright K, Dibert E, Koehler V, Lockhart S, Calonge N. Population-based versus practice-based recall for childhood immunizations: a randomized controlled comparative effectivenes — View Citation
Kempe A, Saville AW, Dickinson LM, Beaty B, Eisert S, Gurfinkel D, Brewer S, Shull H, Herrero D, Herlihy R. Collaborative centralized reminder/recall notification to increase immunization rates among young children: a comparative effectiveness trial. JAMA Pediatr. 2015 Apr;169(4):365-73. doi: 10.1001/jamapediatrics.2014.3670. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects receiving influenza vaccine based on zero notices versus those receiving 1, 2 or 3 notices. | The primary outcome is receipt of influenza vaccine by children receiving zero notices compared to those receiving 1, 2 or 3 notices. | 6 months | |
Secondary | Number of subjects receiving influenza vaccine based on demographic subgroups. | This outcome will categorize the number of influenza vaccines administered by subgroups, e.g.: Urban/Rural, Pediatrics/Family Practice, and age from 6m-1.9 yr., 2-10.9 yr. and 11-17.9 yr. | 6 months | |
Secondary | Number of subjects <9 years of age that will receive an additional vaccine. | If the subject is <9 years of age, they are required to received a second vaccine at least 1 month after receiving the initial vaccine. | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246100 -
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado
|
N/A | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
Completed |
NCT03735147 -
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
|
Phase 4 | |
Completed |
NCT02831608 -
Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis
|
Phase 4 | |
Completed |
NCT02560909 -
Adjuvanted Influenza Vaccine in Stem Cell Transplant
|
Phase 4 | |
Withdrawn |
NCT01623232 -
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
|
Phase 1/Phase 2 | |
Completed |
NCT00961337 -
Evaluation of a School-based Influenza Vaccination Program
|
Phase 4 | |
Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
Completed |
NCT00222638 -
Influenza Vaccination and Oral Anticoagulant Therapy
|
Phase 4 | |
Active, not recruiting |
NCT03734237 -
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
|
Phase 4 | |
Completed |
NCT01013675 -
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly
|
Phase 2 | |
Completed |
NCT00306995 -
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
|
Phase 2 | |
Completed |
NCT01310413 -
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
|
Phase 3 | |
Completed |
NCT00449670 -
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults
|
Phase 3 | |
Completed |
NCT01788228 -
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
|
Phase 3 | |
Completed |
NCT00296270 -
Memory for Flu Facts and Myths and Effects on Vaccine Intentions
|
N/A | |
Recruiting |
NCT05521763 -
Influenza Vaccine Uptake Among Healthcare Workers
|
N/A | |
Completed |
NCT00718120 -
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
|
Phase 3 | |
Completed |
NCT00430521 -
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
|
Phase 2 |